この記事の翻訳を準備しています。それまでの間、英語の原文を表示します。
規制と法律 · 1996/10/91 分で読めます
International Conference on the Virological Safety of Plasma Derivatives; Public Meeting
ローカル自動翻訳 · 情報源の原言語
概要
The Food and Drug Administration (FDA), Center for Biologics Evaluation and Research (CBER), is announcing a public meeting that will address the risks posed by blood-borne viruses that persist in human plasma-derived products. CBER is sponsoring the meeting with the National Heart, Lung, and Blood Institute of the National Institutes of Health, the Centers for Disease Control and Prevention, The World Health Organization, and the International Association of Biological Standards. The goals of the meeting include assessing the virological safety of currently available plasma-derived products and gathering information useful in the evaluation of such products.
情報源の原言語: Federal Register — All Documents原文の発表を開く →